Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PharmAsia News’ Top 2008 Stories

This article was originally published in PharmAsia News

Executive Summary

With our first year of publishing PharmAsia News closing, we take this opportunity to look back at the top stories published in 2008. In case you missed them, here is your opportunity to check out the top stories covered this year in PharmAsia News, broken down by region

You may also be interested in...

Drug Controller General Of India Surinder Singh On India’s Regulatory Overhaul: An Interview With PharmAsia News

Surinder Singh took the mantle of the Drug Controller General of India a few months ago. From being a microbiologist to handling the most important regulatory position in the Indian drug industry, Singh is already confronted with a host of challenges. Overhauling the regulatory system, dealing with vexatious registration issues and advocating for Indian drug industry on global forums, Singh has been working on an extremely tight schedule. Singh took time off from his busy routine and sat down with PharmAsia News' India bureau to discuss India's impending regulatory overhaul (PharmAsia News, Sept. 11, 2008).

Ranbaxy Will Begin U.S. Sales Of Generic Nexium In 2014 Under Deal Ending Patent Litigation

China’s MOH-SFDA Merger: Analysts Weigh In

SHANGHAI - China has reorganized the Ministry of Health and put the State FDA under its jurisdiction. The State Council's institutional restructuring scheme was officially approved March 15 at the first session of the 11 National People's Congress held in Beijing

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts